( The introduction of the drug-eluting stent (DES) has been considered one of the most significant developments in cardiology – revolutionizing treatment protocols for CAD patients and improving outcomes dramatically. But as their use has grown, reports of adverse events and potential risk factors have dimmed the luster of first-generation DES and led to a debate within the cardiovascular community that is intense and ongoing.
Efforts to correct perceived weaknesses in current coated devices have led to an intense level of activity, with major players being joined by more than a dozen companies with the technology and expertise to make their mark on the DES landscape. These participants are exploring a number of new and innovative approaches that include novel stent geometries specifically designed for the dual purpose of lumen integrity and drug delivery, non-durable stents, new classes of drugs, and novel coating application technologies and strategies. With drug coated stents now accounting for nine of every ten stenting procedures, the stakes are significant.
These findings are contained in a new report, Drug-eluting Stents: The Next Generation. The report is designed to provide readers with a detailed understanding of enabling technologies, candidate devices, market participants and commercial prospects.
More information is available at www.greystoneassociates.org
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
www.greystoneassociates.org Source: Greystone Associates
For more information:
Last updated on: 27/08/2010
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.